Literature DB >> 2036976

Two high affinity binding sites for pituitary adenylate cyclase-activating polypeptide have different tissue distributions.

B D Shivers1, T J Görcs, P E Gottschall, A Arimura.   

Abstract

Two bioactive products of pituitary adenylate cyclase-activating polypeptide (PACAP) prohormone have been isolated from ovine hypothalamus: PACAP38 with 38 residues and PACAP27 corresponding to the N-terminal 27 residues of PACAP38. Immunocytochemical and RIA results support the existence of PACAP in the rat brain, posterior pituitary, and various peripheral tissues. Furthermore, high affinity PACAP-binding sites have been detected in the rat brain, anterior pituitary, and cultured astrocytes which differ from those in lung, liver, and cultured mouse splenocytes. In the present study additional rat tissues were examined to elucidate the location and characteristics of PACAP-binding sites using [125I] PACAP27 with conventional methods of receptor autoradiography and RRA. Binding specificity was established by displacement with unlabeled PACAP27 or a related peptide, vasoactive intestinal polypeptide (VIP). PACAP27-binding sites were localized autoradiographically in the testis, epididymis, adrenal gland, lung, liver, prostate gland, and seminal vesicle; binding sites were not detected in the heart, kidney, or thymus. In the testis and epididymis, a PACAP27-binding site was localized on germinal cells and in the adrenal gland on medullary chromaffin cells. Excess VIP did not displace PACAP27 binding localized in these three tissues. A site with a greater affinity for PACAP27 than for VIP was detected in adrenal gland and epididymis, characteristic of a site recognized previously in hypothalamus, anterior pituitary, and cultured astrocytes. The PACAP-specific site was more abundant in these tissues than a second site to which PACAP27 and VIP bound with similar affinities. Accordingly, the first site has been named type I. In lung, liver, prostate, and seminal vesicle, VIP displaced PACAP27 binding localized autoradiographically. Lung and liver contained an abundant site to which PACAP27 and VIP bound with similar affinities. This binding site, measured previously in lung, liver, and cultured splenocytes, may be shared by PACAP and VIP and has been named type II. Taken together, these data support the existence of two high affinity binding sites for PACAP with different tissue distribution.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2036976     DOI: 10.1210/endo-128-6-3055

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  35 in total

Review 1.  Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1.

Authors:  Anthony J Harmar; Jan Fahrenkrug; Illana Gozes; Marc Laburthe; Victor May; Joseph R Pisegna; David Vaudry; Hubert Vaudry; James A Waschek; Sami I Said
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

2.  Regulation of spinal dynorphin 1-17 release by endogenous pituitary adenylyl cyclase-activating polypeptide in the male rat: relevance of excitation via disinhibition.

Authors:  Nai-Jiang Liu; Stephen A Schnell; Stefan Schulz; Martin W Wessendorf; Alan R Gintzler
Journal:  J Pharmacol Exp Ther       Date:  2010-10-25       Impact factor: 4.030

Review 3.  A VIP hybrid antagonist: from developmental neurobiology to clinical applications.

Authors:  I Gozes; M Fridkin; D E Brenneman
Journal:  Cell Mol Neurobiol       Date:  1995-12       Impact factor: 5.046

4.  Impairment of mossy fiber long-term potentiation and associative learning in pituitary adenylate cyclase activating polypeptide type I receptor-deficient mice.

Authors:  C Otto; Y Kovalchuk; D P Wolfer; P Gass; M Martin; W Zuschratter; H J Gröne; C Kellendonk; F Tronche; R Maldonado; H P Lipp; A Konnerth; G Schütz
Journal:  J Neurosci       Date:  2001-08-01       Impact factor: 6.167

Review 5.  VIP as a cell-growth and differentiation neuromodulator role in neurodevelopment.

Authors:  J M Muller; V Lelievre; L Becq-Giraudon; A C Meunier
Journal:  Mol Neurobiol       Date:  1995 Apr-Jun       Impact factor: 5.590

Review 6.  Neuropeptides of the pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide/growth hormone-releasing hormone/secretin family in testis.

Authors:  Min Li; Akira Arimura
Journal:  Endocrine       Date:  2003-04       Impact factor: 3.633

7.  Molecular cloning and functional expression of the pituitary adenylate cyclase-activating polypeptide type I receptor.

Authors:  J R Pisegna; S A Wank
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

8.  Pituitary adenylate cyclase activating peptide, a novel VIP-like gut-brain peptide, relaxes the guinea-pig taenia caeci via apamin-sensitive potassium channels.

Authors:  H Schwörer; S Katsoulis; W Creutzfeldt; W E Schmidt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-11       Impact factor: 3.000

9.  Effects of PACAP on survival and renal morphology in rats subjected to renal ischemia/reperfusion.

Authors:  Peter Szakaly; Peter Kiss; Andrea Lubics; Tamas Magyarlaki; Andrea Tamas; Boglarka Racz; Istvan Lengvari; Gabor Toth; Dora Reglodi
Journal:  J Mol Neurosci       Date:  2008-05-14       Impact factor: 3.444

10.  Pituitary adenylate cyclase-activating peptide (PACAP) immunolocalization in lymphoid tissues of the rat.

Authors:  F Gaytan; A J Martinez-Fuentes; F Garcia-Navarro; H Vaudry; E Aguilar
Journal:  Cell Tissue Res       Date:  1994-05       Impact factor: 5.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.